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Abstract
Tumor development, growth, and metastasis depend on the provision of an adequate vascular supply. This can be due to
regulated angiogenesis, recruitment of circulating endothelial progenitors, and/or vascular transdifferentiation. Our
previous studies showed that retinoic acid (RA) treatment converts a subset of breast cancer cells into cells with significant
endothelial genotypic and phenotypic elements including marked induction of VE-cadherin, which was responsible for
some but not all morphological changes. The present study demonstrates that of the endothelial-related genes induced by
RA treatment, only a few were affected by knockdown of VE-cadherin, ruling it out as a regulator of the RA-induced
endothelial genotypic switch. In contrast, knockdown of the RA-induced gene COUP-TFII prevented the formation of
networks in Matrigel but had no effect on VE-cadherin induction or cell fusion. Two pan-kinase inhibitors markedly blocked
RA-induced VE-cadherin expression and cell fusion. However, RA treatment resulted in a marked and broad reduction in
tyrosine kinase activity. Several genes in the TGFb signaling pathway were induced by RA, and specific inhibition of the
TGFb type I receptor blocked both RA-induced VE-cadherin expression and cell fusion. Together these data indicate a role
for the TGFb pathway and COUP-TFII in mediating the endothelial transdifferentiating properties of RA.
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Introduction
Tumor growth and metastasis are dependent upon the presence
of an adequate vascular supply. A breast tumor that is unable to
properly vascularize can grow no larger than 4 mm
3 or spread,
and it was traditionally thought that angiogenesis was the sole
method by which tumor cells can acquire an adequate vasculature.
As a tumor expands, central necrosis occurs due to hypoxia and
nutrient deprivation[1] leading to the production of angiogenic
factors that recruit blood vessels from neighboring vessels or
progenitor cells[2]. However, clinical trials with angiogenesis
inhibitors have been disappointing.
The phenomenon of vasculogenic mimicry is one potential
mechanism for tumor resistance to angiogenesis inhibitors [3] and
increased patient mortality [4]. Vasculogenic mimicry refers to the
ability of highly aggressive tumor cells to form matrix-rich
networks surrounding spheroidal clusters of tumor cells in the
absence of tumor necrosis and angiogenesis [5]. Observational
data indicates that these tumor cells may also be able to interact
with endothelial cells and line channels that conduct blood into the
tumor [6,7]. This phenomenon has been observed in vivo in
melanoma, prostate, ovarian, liver, breast cancers, astrocytomas,
mesothelial sarcomas, and sarcomas, as well as in vitro in highly
aggressive melanoma and bladder cancer cell lines
[6,7,8,9,10,11,12,13,14,15,16,17]. Tumor cells exhibiting vascu-
logenic mimicry can upregulate the expression of endothelial
specific genes [5,18]. While markers of vasculogenic mimicry are
being identified, the mechanism regulating vasculogenic mimcry
or the factors inducing the phenomenon are still unknown.
Previously, we have shown that treatment of SKBR-3 breast
cancer cells with 9-cis-retinoic acid (RA) induces the expression of
endothelial specific genes, including VE-cadherin [19]. When
these cells are grown in Matrigel, they form network-like
structures, and RA treated SKBR-3 cells are able to fuse with
each other. Additionally, RA-treated SKBR-3 cells are able to
interact with HUVEC cells in Matrigel to form mixed vessel
networks. Two factors, the HMG box protein SOX9 and the ets-
family member ER81, were necessary for the RA induced
expression of VE-cadherin [19].
In the present study we eliminate VE-cadherin as a master
regulator of the RA-induced endothelial gene upregulation by
showing that few of the many endothelial-related genes are
affected by knockdown of VE-cadherin. COUP-TFII is an orphan
nuclear receptor that is induced by RA treatment and involved in
venous differentiation[20,21,22]. We found that knockdown of
COUP-TFII prevented the formation of networks in Matrigel but
had no effect on VE-cadherin induction and subsequent cell
fusion. Surprisingly, considering the important role of tyrosine
kinases in angiogenesis and vascular development, tyrosine kinases
are not important in RA-mediated vascular mimicry [23]. In fact,
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tyrosine kinase activity. However, several genes in the TGFb
signaling pathway were induced by RA, and specific inhibition of
the TGFb type I receptor blocked both RA-induced VE-cadherin
expression and cell fusion. Together these data indicate a role for
the TGFb pathway and COUP-TFII in mediating the endothelial
transdifferentiating properties of RA.
Results
VE-cadherin, COUP-TFII, and NRP1 are not master
regulators of endothelial transdifferentiation
We have previously shown that SOX9 and ER81 expression are
necessary but not sufficient for RA-induced endothelial transdif-
ferentiation. Since VE-cadherin is important for both vasculogen-
esis and angiogenesis, we wanted to determine which RA induced
genes were dependent upon VE-cadherin expression. In our
previous study, we treated SKBR-3 cells with 10
26 M RA. We
repeated the experiment using 10
27 M RA (ArrayExpress
accession: E-MEXP-2417) and found a similar induction of RA
induced endothelial specific genes (Table 1). Using Ingenuity
Pathway Analysis, we determined that the genes regulated by RA
treatment belonged to the tumor morphology pathway (Table S1),
cardiovascular development (Table S2), and hematological and
coagulation pathways (Table S3).
We then used microarray analysis to compare the genes induced
by RA in the presence and absence of VE-cadherin (ArrayExpress
accession: E-MEXP-2418) to analyze which induced genes are
regulated by VE-cadherin. We transfected SKBR-3 cells with
control luciferase siRNA or VE-cadherin siRNA. After 8 hours,
cells were treated with 10
27M RA. The cells were allowed to grow
for an additional 48 hours before RNA was collected and
processed for microarray analysis.
Analysis of the microarray data using BRB Array Tools and the
RMA Methodology yields 208 unique genes that are differentially
regulated as a result of VE-cadherin siRNA transfection. We
found that 10 of the genes we had identified as being endothelial
related in our original microarray were differentially regulated in
the presence of VE-cadherin siRNA (Table 2). Of those, only 3
genes – VE-cadherin itself, HMGCS1, and KLF5 – were reduced
(compared to RA and control siRNA) in the absence of VE-
cadherin. As expected VE-cadherin was markedly reduced,
HMGCS1 and KLF5 were modestly affected (1.59 and 1.3 fold
respectively). Seven other endothelial related genes were further
induced (albeit slightly; 1.2–1.6 fold) in the absence of VE-
cadherin. These data suggests that VE-cadherin may regulate
some endothelial-related genes, but it does not serve as a master
regulator of endothelial transdifferentiation.
Since VE-cadherin is not responsible for the RA mediated
induction of endothelial genes, we next examined the roles of
Table 1. Top 25 Endothelial Related Genes Regulated by RA.
Gene Symbol Description
Fold Change (RA/
Control) p-value
CDH5 cadherin 5, type 2, VE-cadherin (vascular epithelium) 10 7.0E-07
TFPI2 tissue factor pathway inhibitor 2 6.34 7.0E-07
BDKRB2 bradykinin receptor B2 5 2.0E-05
EFNB2 ephrin-B2 5 3.0E-03
CP ceruloplasmin (ferroxidase) 5 1.1E-03
SELE selectin E (endothelial adhesion molecule 1) 5 3.6E-06
SELL selectin L (lymphocyte adhesion molecule 1) 5 1.0E-06
ID1 inhibitor of DNA binding 1, dominant negative helix-loop-helix protein 3.33 9.2E-05
COUP-TFII nuclear receptor subfamily 2, group F, member 2 3.33 3.4E-05
PLAU plasminogen activator, urokinase 3.33 2.2E-03
COX1 prostaglandin E synthase 3.33 4.6E-06
CAV1 caveolin 1, caveolae protein, 22 kDa 2.5 6.0E-04
NRP1 neuropilin 1 2.5 2.0E-04
TGFBR2 transforming growth factor, beta receptor II (70/80 kDa) 2.5 3.4E-03
ANXA2 annexin A2 2 2.6E-04
BDKRB1 bradykinin receptor B1 2 1.3E-04
CAV2 caveolin 2 2 1.5E-02
EPAS1 endothelial PAS domain protein 1 2 3.2E-03
SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1),
member 1
2 3.5E-03
TGFB2 transforming growth factor, beta 2 2 2.8E-03
EPHB4 EPH receptor B4 21.5 7.5E-03
F12 coagulation factor XII (Hageman factor) 21.5 4.1E-03
TGFBR1 transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53 kDa) 21.9 1.6E-02
TGFB3 transforming growth factor, beta 3 22.5 3.89E-05
doi:10.1371/journal.pone.0010023.t001
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specific genes. COUP-TFII is an orphan nuclear receptor involved
in venous differentiation, whereas NRP1 is a transmembrane
glycoprotein that promotes artery formation. Both were signifi-
cantly induced by RA [24,25]. In addition to looking at the
regulation of VE-cadherin, COUP-TFII, and NRP1, we used the
expression of three other RA-regulated endothelial related genes –
EfnB2, TFPI2, and COX1 – as markers of endothelial
transdifferentiation. EfnB2, a ligand for the Eph receptor B4
(EphB4), is induced by NRP1 and is involved in artery
formation[24,25]. TFPI2, a serine protease inhibitor, is involved
in the clotting cascade[26], whereas COX1 is a gene expressed by
endothelial cells and involved in inflammation[27,28]. To
determine whether NRP1 or COUP-TFII can serve as regulators
of endothelial transdifferentiation, we reduced the expression of
these genes using siRNA, treated them with RA for 48 hours, and
performed qPCR assays to determine the expression levels of
various endothelial specific genes (Figure 1). qPCR analysis verifies
the microarray result indicating that VE-cadherin may regulate
the expression of TFPI2. Similar to VE-cadherin, neither COUP-
TFII nor NRP1 regulate the expression of the other endothelial
genes we measured. The 2.5 fold induction of NRP1 by RA
observed by microarray analysis was not confirmed by qPCR
further ruling out a role for this molecule. Taken together, these
results indicate that VE-cadherin, COUP-TFII, and NRP1 do not
regulate one another.
Receptor tyrosine kinase activity is not important for
RA-mediated VE-cadherin induction
We next examined the roles of kinases in regulating VE-
cadherin expression and network formation. Activation of kinases
by their ligands is important during most stages of angiogenesis
and vasculogenesis. During vasculogenesis, binding of basic
fibroblast growth factor to its receptor results in the differentiaton
of mesodermal cells into hemangioblasts, precursors of both
hematopoietic cells and endothelial cells[29,30]. VEGF binding to
its receptors, VEGFR-2 and VEGFR-1, is necessary for further
differentiation of endothelial cells, endothelial cell-cell contacts,
and vascular tube formation[31,32,33,34]. Next, the binding of
angiopoietin-1 (Ang1) to its receptor, Tie2, results in increased
stabilization of the vascular wall via the recruitment of
pericytes[35,36,37]. At this point, vasculogenesis is complete and
angiogenesis begins to model a mature vascular system. VEGF
works to loosen cell-contacts and breaks down the basement
membrane so that endothelial cells can migrate and form
sprouts[38]. Next, platelet derived growth factor (PDGF) binds
to its receptor, PDGFbR, and recruits pericytes to strengthen the
capillary wall[39]. TGF-b signaling via the TGFb type I receptor
has both pro-angiogenic and anti-angiogenic effects on prolifer-
ation and migration[40,41].
Since kinases play important roles in most steps of angiogen-
esis and vasculogenesis, we were interested in determining
whether kinase activity is necessary for expression of VE-
cadherin in RA treated SKBR-3 cells. Previous studies have
indicated that Genistein plays a role in regulating VE-cadherin
expression and vascular network formation in HUVECs [42].
Following an hour of pre-treatment with two pan-kinase
inhibitors, Genistein (Figure 2a) and SD705701, a novel kinase
inhibitor (Figure 2b), VE-cadherin expression was lost following
48 hours of RA treatment. Each experiment was conducted
three times and representative blots are shown. Since Genistein
and SD705701 both target tyrosine kinases we next tested the
roles of receptor tyrosine kinases (RTKs) in regulating VE-
cadherin expression. SKBR-3 cells were treated with control
ethanol or 10
27 M RA for 48 hours and tyrosine kinase activity
was analyzed using a Human Phospho-Receptor Tyrosine
Kinase array. Tyrosine kinase phosphorylation was broadly
and markedly reduced following treatment with RA (Figure 2c).
Although the Tyrosine Kinase array demonstrates a decrease in
tyrosine kinase activity following RA treatment, we decided to
examine the role of ERBB2 in regulating VE-cadherin
expression. SKBR-3 cells are known to overexpress ERBB2,
and it was a candidate regulator of VE-cadherin expression. Pre-
treatment of SKBR-3 cells with AG825, an ERBB2 specific
inhibitor, for 1 hour prior to a 48 hour treatment with RA was
unable to regulate VE-cadherin expression (Figure 2d). The only
receptor tyrosine kinase whose activity appears to remain the
stable following RA treatment is DTK. DTK is a member of the
AXL family of receptor tyrosine kinases. Downregulation of
DTK expression via DTK specific siRNA (Figure 2e) was unable
to inhibit VE-cadherin mRNA expression (Figure 2f), thereby
eliminating its role as a regulator of VE-cadherin. In addition to
inhibiting receptor tyrosine kinases, both Genistein and
SD705701 also have activity against serine/threonine kinases,
including the TGFb pathway.
Table 2. Endothelial-Related Genes Regulated by RA and VE-cadherin.
Gene Symbol Gene Name
Fold Change with
RA + Luc siRNA
Fold Change with RA + VE-
cadherin siRNA
CCL2 Chemokine Ligand 2 2 (p=2.0E-02) 2 (p=1.1E-04)
CDH5 VE-cadherin 10 (p=7.0E-07) 23.8 (p=6.5E-06)
CTSS Cathepsin S 5 (p=1.7E-04) 1.6 (p=4.1E-04)
HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 1.4 (p=9.1E-03) 21.6 (p=6.5E-03)
HMOX1 Heme oxygenase 1 1.7 (p=3.7E-03) 1.3 (p=1.0E-02)
IGFBP3 Insulin-like Growth Factor Binding Protein 3 2.5 (p=1.7E-03) 1.4 (p=1.4E-03)
KLF5 Kruppel Like Factor 5 2 (p=1.6E-03) 21.3 (p=2.4E-02)
MGP Matrix Gla Protein 10 (p=2.9E-06) 1.2 (p=2.9E-02)
PLAU Plasminogen Activator, Urokinase 3.3 (p=2.2E-03) 1.7 (p=6.3E-04)
TGFB2 TGFb2 2 (p=2.8E-03) 1.5 (p=1.6E-03)
doi:10.1371/journal.pone.0010023.t002
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but TGFb1 alone is unable to induce VE-cadherin
expression
Ingenuity Pathway Analysis of our microarray data comparing
control cells to RA treated cells indicates that several members of
the TGFb family of serine/threonine kinases were regulated by
RA. These include bone morphogenic protein 7 (BMP7), SMAD1,
SMAD3, transforming growth factor-b 1 (TGFb1), and trans-
forming growth factor-b receptor 2 (TGFbR2) (Table 3). Treat-
ment of SKBR-3 cells with SB431542, a specific TGFbR1 kinase
inhibitor, completely blocked the RA mediated expression of VE-
cadherin (Figure 3a). Inhibition of TGFbR1 activity was
confirmed via qPCR using PAI-1 activity as a marker
(Figure 3b). However, treatment with TGFb1, alone, is unable
to induce VE-cadherin expression in the absence of RA treatment
(Figure 3c). These results indicate that TGFbR1 activity is
necessary but not sufficient for the RA mediated induction of
VE-cadherin expression.
VE-cadherin and TGFbR1 are necessary for cell fusion, but
not network formation, while COUP-TFII is necessary for
network formation but not cell fusion
While neither VE-cadherin, COUP-TFII, nor TGFbR1 are
master regulators of the endothelial genetic program, they may
play important roles in the cell fusion and network formation that
occurs following RA treatment [19]. SKBR-3 cells were
transfected with control siRNA and pretreated for 24 hours with
either ethanol control or 10
27 M RA for 24 hours prior to plating
in Matrigel. When control treated SKBR-3 cells are gown in
Matrigel, they grow as grape like clusters (Figure 4a) and do not
fuse (inset). In the presence of RA, SKBR-3 cells form network-like
structures (Figure 4b) and begin to fuse, and boundaries between
cells are indistinguishable (inset). In the presence of VE-cadherin
siRNA, control SKBR-3 cells grow like the control siRNA
transfected SKBR-3 (Figure 4c) and do not fuse (inset); however,
VE-cadherin siRNA transfected cells treated with RA still form
rudimentary networks (Figure 4d), but cell fusion is greatly
Figure 1. VE-cadherin, COUP-TFII, and NRP1 are not master regulators of retinoic acid mediated vasculogenic mimicry. Following
siRNA transfection with luciferase control or siRNA targeting VE-cadherin, COUP-TFII, or NRP1, cells were treated with control ethanol or RA for
48 hours. qPCR analysis was performed to assess knockdown of VE-cadherin (a), COUP-TFII (b), NRP1 (c), COX1 (d), TFPI2 (e), and EFNB2 (f). Samples
have been labeled as follows: 1 - Control, Luciferase siRNA; 2 - RA, Luciferase siRNA; 3 - Control, VE-cadherin siRNA; 4 - RA, VE-cadherin siRNA; 5 -
Control, COUP-TFII siRNA; 6 - RA, COUP-TFII siRNA; 7 - Control, NRP1 siRNA; 8 - RA, NRP1 siRNA.
doi:10.1371/journal.pone.0010023.g001
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activity. Pre-treatment of SKBR-3 cells for 1 hour with 10 mM, 50 mM or 100 mM of Genistein prior to a 48 hour RA treatment results in a loss of VE-
cadherin expression and tyrosine phosphorylation (a). Pre-treatment with the novel pan-kinase inhibitor, SD705701, also results in a loss of VE-
cadherin expression in a dose-dependent manner (b). A Human Phospho-Receptor Tyrosine Kinase array demonstrates that RA treatment results in
the loss of tyrosine kinase phosphorylation (c). A key for this array is as follows: Control - A1, A2, A23, A24, F1, F2, F23, F24; EGFR - B1, B2; EphB4 - E9,
E10; ErbB2 - B3, B4; ERBB3 - B5, B6; EGFR - B11, B12, B13, B14; Dtk - B23, B24; Mer - C1, C2; Tie-2 - D1, D2; TrkA - D3, D4; VEGFR2 - D11, D12. Inhibition
of ERBB2 activity with AG825 is unable to inhibit VE-cadherin expression (d). Samples are labeled as follows: 1 - Control; 2 - RA; 3 - Control, Ethanol; 4 -
RA, Ethanol; 5 - Control, 100 mm Genistein; 6 - RA, 100 mM Genistein; 7 - Control, DMSO; 8 - RA, DMSO; 9 - Control, 50 mM AG825; RA - 50 mM AG825.
Inhibition of DTK expression with siRNA (e) is unable to inhibit VE-cadherin expression (f).
doi:10.1371/journal.pone.0010023.g002
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vehicle does not result in network formation or cell fusion in the
absence of RA (Figure 4g), but does result in network formation
and cell fusion when treated with RA (Figure 4h). Treatment of
SKBR-3 cells with the TGFbR1 inhibitor (Figure 4i), SB431542,
does not alter morphology in the absence of RA. SB431542
(Figure 4j) treated SKBR-3 cells that are treated with RA do not
fuse (inset) but do form networks (Figure 4j) much like RA treated
VE-cadherin siRNA transfected SKBR-3 cells. These results
indicate that VE-cadherin expression is necessary for cell fusion,
but not the network formation phenomenon. Additionally,
inhibiting TGFbR1 activity mimics the effects of a loss of VE-
cadherin providing further evidence that TGFbR1is necessary for
VE-cadherin expression.
When SKBR-3 cells are transfected with COUP-TFII siRNA,
untreated cells grow as clusters (Figure 4e) and do not fuse
(inset). On the other hand, treatment with RA results in cell
fusion (Figure 4f, inset), but network formation does not occur
(Figure 4f). These results indicate that COUP-TFII, which does
not regulate VE-cadherin expression, is not responsible for cell
fusion; however, the loss of COUP-TFII prevents the formation
of networks.
Discussion
The role of this study was to further understand the
mechanism of RA mediated endothelial transdifferentiation in
SKBR-3 breast cancer cells. We have previously shown that RA
induces the expression of genes associated with the endothelial
lineage and allows for interaction of RA treated SKBR-3 cells
with HUVEC cells in Matrigel. We have shown that ER81 and
SOX9 are necessary but not sufficient for inducing VE-cadherin
expression. In this study, we have shown that a physiologic dose
of RA regulates many genes. Some of the affected pathways are
the cancer growth regulation pathway, cardiovascular develop-
ment, and the hematological and coagulation pathways. Genes
associated with proliferation and cancer are decreased, as is
expected with RA treatment [43,44]. As we have previously
shown, genes associated with the endothelial lineage are induced
[19]. These results may help explain the mixed results of RA
treatment in clinical trials. In individuals with specific molecular
profiles, RA treatment, while decreasing cell growth, may also
push cells along deleterious differentiation pathways, such as the
Figure 3. TGFbR1 kinase activity is necessary for VE-cadherin expression. A one hour pre-treatment with SB431542, a TGFbR1 kinase
specific inhibitor, prior to a 48 hour RA treatment results in a loss of VE-cadherin expression in a dose-dependent manner (a). Treatment with
SB431542 decreases PAI-1 activity, confirming TGFbR1 blockade (b).The samples are as follows: 1 - Control; 2 - RA; 3 - Control, 10 mM SB431542; 4 - RA,
10 mM SB431542; 5 - Control - 50 mM SB431542; 6 - RA, 50 mM SB431542. Treatment with 10 ng/ml of TGFb, alone, does not induce VE-cadherin
expression in the absence of RA treatment (c).
doi:10.1371/journal.pone.0010023.g003
Table 3. TGFb Family Members Regulated by RA Treatment.
Gene Name Fold Change p-value
TGFB2 1.9 2.8E-03
TGFB3 0.4 3.9E-05
TGFBI 2.8 1.0E-04
TGFBR1 0.5 1.6E-02
TGFBR2 2.7 2.2E-05
BMP3 1.9 1.1E-02
BMP7 0.4 6.2E-04
SMAD1 2.3 1.3E-02
SMAD3 2.4 2.1E-04
GRB2 1.9 2.5E-03
doi:10.1371/journal.pone.0010023.t003
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PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e10023Figure 4. COUP-TFII is necessary for network formation while TGFbR1 activity is necessary for cell fusion. Low power images (206)o f
control siRNA transfected untreated SKBR-3 cells show that they grow as clusters of individual cells in Matrigel (a) without any cell fusion (inset, 406).
Upon RA treatment, the cells begin to form networks (b) with cell fusion (inset). Loss of VE-cadherin expression using VE-cadherin siRNA does not
affect untreated SKBR-3 cells (c, inset). However, a loss of VE-cadherin expression with concomitant RA treatment results in a preservation of network
formation (d), but a loss of cell fusion (inset). Like the VE-cadherin siRNA treatment, COUP-TFII siRNA treatment does not affect the growth patterns of
untreated SKBR-3 cells (e, inset). However, treatment with COUP-TFII siRNA does not affect the fusion of RA treated SKBR-3 cells (f, inset), but it does
inhibit network formation (f). Untreated SKBR-3 cells also grow as clusters of unfused individual cells in the absence of RA treatment (g, inset), and RA
treatment results in network formation and cell fusion (h, inset). Pre-treatment with 50 mM SB431542 does not affect the growth patterns of
untreated SKBR-3 cells (i, inset). Pre-treatment with SB431542 prior to RA treatment does not alter network formation (j), but inhibits cell fusion (j,
inset).
doi:10.1371/journal.pone.0010023.g004
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genic mimicry, and thus, an alternative mechanism of tumor
vascularization. We utilized several markers of endothelial
transdifferentiation – VE-cadherin, COUP-TFII, NRP1, EfnB2,
TFPI2, and COX1 - and analyzed the roles of VE-cadherin,
COUP-TFII, and NRP1 as master regulators of vasculogenic
mimicry. Knockdown of VE-cadherin expression using siRNA
was unable to inhibit the expression of endothelial genes when
analyzed using both qPCR and microarray analysis. Surprisingly,
the loss of VE-cadherin seemed to promote the expression of
some pro-angiogenic genes in RA treated SKBR-3 cells.
However, down-regulation of VE-cadherin expression is one of
the first steps of angiogenesis; thus, this may, in fact, promote
further branching morphogenesis. VE-cadherin siRNA also
potentiated the RA mediated increase in coagulation/hemato-
logical factors, which is in line with the current understanding of
the role of VE-cadherin in the coagulation cascade [45]. The loss
of VE-cadherin did not have an effect on the growth regulatory
genes that were affected by RA treatment. We also used siRNA
technology to knockdown COUP-TFII and NRP1 and study the
expression of endothelial-related genes on the qPCR level.
Neither of these genes appears to play a role in regulating the
expression of endothelial specific genes.
Given the importance of kinases in various steps of vasculo-
genesis and angiogenesis, we wanted to know whether kinases
played a role in regulating the expression of endothelial-related
genes. For these studies, we used VE-cadherin as a marker for
endothelial transdifferentiation. We find that treatment of SKBR-
3 cells with genistein results in a loss of VE-cadherin expression,
which is similar to that observed in HUVECs treated with
genistein [46]. Another pan-kinase inhibitor, SD705701, had
similar effects on VE-cadherin expression at much lower
concentrations. To determine whether tyrosine kinases are
involved in this process, we utilized a receptor tyrosine kinase
array to determine the activity of kinases following RA treatment.
We found that RA treatment leads to a loss of tyrosine kinase
activity. These results indicate that while kinase activity is
necessary for VE-cadherin expression, it is independent of
receptor tyrosine kinases.
Following closer analysis of our microarray data, we identified
several members of the TGF-b family of cytokines that are
induced as a result of RA treatment. SD705701 is known to have
activity against serine/threonine kinases, and genistein, while
inducing the expression of TGF-b has also been shown to inhibit
TGFbR1 mediated phosphorylation of p38 MAPK [47]. TGF-b
treatment, alone, is unable to induce VE-cadherin expression;
however, inhibition of TGFbR1 activity using the specific kinase
inhibitor, SB431542, inhibits RA-induced VE-cadherin expres-
sion. These results imply that activity of TGFbR1 is necessary but
not sufficient for VE-cadherin expression, and presumably
complete endothelial transdifferentiation. Additionally, the activa-
tion of ALK1 type I receptors induces the phosphorylation of
SMAD1, SMAD5, and transcription of Id1, while activation of
ALK5 receptors induces the phosphorylation of SMAD2 and the
transcription of PAI-1 [40]. ALK1 has been shown to stimulate
endothelial proliferation and migration, while ALK5 activation
inhibits these processes. Our microarray analysis indicates that Id1
expression is induced as a result of RA treatment. Thus, the ALK1
type I receptor may also play a role in RA induced endothelial
transdifferentiation.
We have also shown that network formation and cell fusion
are distinct processes during vasculogenic mimicry. VE-cadherin
expression, as expected, plays a role in mediating the formation
of cell-cell adhesions and cell fusion. Loss of VE-cadherin
expression either directly by VE-cadherin siRNA or indirectly
via inhibition of TGFbR1 kinase is able to inhibit cell fusion in
Matrigel, but does not appear to affect the formation of primitive
network-like structures. On the other hand, loss of COUP-TFII
expression using siRNA is unable to inhibit cell fusion following
RA treatment, but profoundly inhibits network formation.
Proper vascular formation by endothelial cells requires both
processes. Network formation without cell fusion may not allow
for the proper conductance of nutrients to a tumor. In the same
way, cell fusion without network formation will not allow the
lumen-like spaces formed by RA treated SKBR-3 cells to
properly connect with the host vasculature. Thus, both processes
may have to occur to allow for the deleterious effects in cancer
patients.
The presence of vasculogenic mimicry is a negative prognos-
ticator of patient outcomes in human cancers. We have previously
identified a dietary agent, vitamin A, in regulating this process in
breast cancer. We now propose that VE-cadherin expression
induced by RA is regulated by ER81, SOX9, and TGFbR1
activity, while network formation is regulated by COUP-TFII
(Figure 5).
Figure 5. Schematic representation of factors regulating RA-
mediated endothelial transdifferentiation.
doi:10.1371/journal.pone.0010023.g005
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Materials and Reagents
9-cis-RA was obtained from Sigma-Aldrich (Germany), mouse
anti-VE-cadherin was obtained from R&D systems (Minneapolis,
MN) and anti-GAPDH was from Research Diagnostics Inc
(Flanders, NJ). Small interference RNA (siRNA) reagent (SMART
pool) for human VE-cadherin, human COUP-TFII, and human
NRP1 were purchased from Dharmacon (Lafayette, CO). As a
control siRNA, Luc siRNA was used (CGUACGCGGAAUA-
CUUCGA). We obtained TGFb1 (100–21) from PeproTech
(Rocky Hill, NJ), SB431542 from Sigma-Aldrich (Germany).
Genistein was kindly provided by Dr. Partha Banerjee (George-
town University, Washington, DC). The Human Phospho-RTK
Array was performed as per the manufacturer’s instructions (R&D
Systems, Minneapolis, MN).
Cell Culture and Transfection
SKBR-3 cells were obtained from the ATCC (Manassas, VA).
Early passage (, passage 30) SKBR-3 cells were maintained in
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) in 5% CO2 incubator at 37uC.
All transient transfection experiments of plasmid DNA and siRNA
were performed with Amaxa electroporation system (Amaxa, Inc,
Gaithersburg, MD) according to the manufacturer’s protocol.
Inhibitor Studies
SKBR-3 cells were plated in 6-well plates at a density of 500,000
cells per well. Cells were pre-treated with the inhibitor or vehicle
for 1 hour at 37uC in a 5% CO2 incubator. Cells were then
treated with 0.1 mm RA and incubated for an additional 48 hours.
Each experiment was performed a minimum of three times.
Matrigel Assays
For the siRNA experiments, SKBR-3 cells were transfected
with the appropriate siRNA and incubated for 8 hours prior to
the addition of 10
27 M RA. For the inhibitor experiments,
SKBR-3 cells were pre-treated with inhibitor for 1 hour prior to
the addition of 10
27 M RA. Following the addition of RA, the
siRNA transfected cells and inhibitor treated cells were incubated
for 24 hours at 37uCi na5 %C O 2 incubator. The next day, each
well of a 12-well glass-bottom dish (MatTek, Ashland, MA) was
coated with 120 mL of Matrigel (BD Biosciences, San Jose, CA)
and incubated 15 min at 37uC. SKBR-3 cells (100,000 cells/
100 ml medium) were gently plated on top of the Matrigel layer
directly and further incubated 30 min at 37uC. One milliliter of
growth medium was added along with either ethanol control or
the appropriate concentration of 9-cis-RA and inhibitor, if
appropriate. Cells were maintained at 37uC in a 5% CO2
incubator. Cells were visualized using the Olympus IX71 inverted
fluorescent microscope. Each study was performed a minimum of
three times.
Microarray Analysis
SKBR-3 cells were incubated in the presence or absence of 9-
cis-RA (0.1 mM) for 48 h. Total RNA was isolated using Trizol
(Invitrogen) combined with RNAeasy (Qiagen, Valencia, CA) and
was amplified according to the Affymetrix protocol (GeneChip
Eukaryotic Small Sample target labeling Assay Version II)
modified so that the ethanol precipitation cDNA cleanup step
was substituted by Qiaquick PCR purification kit (Qiagen). Biotin-
11-CTP and biotin-16-UTP (Enzo Diagnostics, Farmingdale, NY)
was incorporated during in vitro transcription and 20 ug of the
biotinylated cRNA product was fragmented at 94uC for 25 min.
Treated and untreated samples were amplified, labeled, fragment-
ed and hybridized in the same run. Hybridizations to Affymetrix
HG-U133A GeneChips were performed at 45uC for 16 h followed
by staining and washing as described in the manufacturer’s
instructions. The processed chips were then scanned using an
Affimatrix GeneArray scanner. Grid alignment and raw data
generation were performed using Affymetrix GeneChip 5.0
Software. For quality control, oligo B2 was hybridized to the chip
and the checkerboard pattern in each corner of the chip analyzed.
BioB, bioC and bioD probes are added to each sample to
standardize hybridization, staining and washing procedures. Raw
expression values representing the average difference in hybrid-
ization intensity between oligonucleotides containing single base
pair mismatches, was measured. The data from three independent
experiments was analyzed using BRB Array tools (National
Cancer Institute, Bethesda, MD).
Network Generation
A data set containing gene identifiers and corresponding
expression values was uploaded into Ingenuity Pathway Analysis.
Each gene identifier was mapped to its corresponding gene object
in the Ingenuity Pathways Knowledge Base. Focus genes, were
overlaid onto a global molecular network developed from
information contained in the Ingenuity Pathways Knowledge
Base. Networks of these focus genes were then algorithmically
generated based on their connectivity.
Real-time quantitative PCR
Relative quantification was used to evaluate the raw data
obtained from real-time PCR (7900 HT real time PCR system,
384 well format, Applied Biosystems, Foster City, CA). All probes
were purchased from Applied Biosystems (Foster City, CA). All
standards and unknowns were performed in triplicate. The
average value of the triplicate readings for each unknown was
then divided by the corresponding value for GAPDH RNA to
normalize the data. After normalization, the value obtained for the
treated unknown was divided by the value obtained for the
corresponding untreated sample. The final value obtained was a
measure of the fold change in gene expression for the particular
genes of interest between the treated sample and the untreated
sample. Each experiment was performed at least three times and
the standard error of the means was calculated.
Immunoblotting
Eighty-90% confluent SKBR-3 cells were incubated with
DMEM in the presence or absence of 9-cis-RA for 48 hours
under the indicated conditions. Cells were rinsed twice with PBS
and lysed with buffer containing 1% NP-40, 1% sodium
deoxycholate, 0.1 % SDS, 150 mM NaCl, 10 mM sodium
phosphate, pH 7.2 and complete mini protease inhibitors (Roche
Applied Science, Indianapolis, IN). Cell lysates were clarified by
centrifugation at 14,000 rpm for 10 min at 4uC. Protein
concentration was determined with a Bio-Rad DC reagent (Bio-
Rad, Hercules, CA). After SDS-PAGE, proteins were transferred
to Immobilon P (Millipore, Billerica, MA). Membranes were
blocked with 5% milk in Tris-Buffered Saline containing 0.1%
Tween-20, and incubated with primary antibody overnight at 4uC
and subsequently with HRP-labeled secondary antibody. Proteins
were visualized with ECL reagents (Amersham Biosciences,
Piscataway, NJ) or SuperSignal West Femto (Pierce biotechnology
Inc., Rockford, IL), using X-ray films (Denville Scientific Inc.,
Metuchen, NJ). Each experiment was performed a minimum of
three times.
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